D. Boral Capital Reiterates “Buy” Rating for ImmunityBio (NASDAQ:IBRX)
ImmunityBio (NASDAQ:IBRX – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $30.00 price objective on the stock. Separately, HC Wainwright reaffirmed a “buy” rating on shares of ImmunityBio in a research note on Monday, May […]
ImmunityBio (NASDAQ:IBRX – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $30.00 price objective on the stock. Separately, HC Wainwright reaffirmed a “buy” rating on shares of ImmunityBio in a research note on Monday, May […]
